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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the infectious etiologic agent associated with
Kaposi’s sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. It has
been  shown  that  high  KSHV  prevalence  and  high  incidence  of  both  classic  KS  and  AIDS-
associated KS are found mostly among people of Uygur ethnicity in Xinjiang, while people of Han
ethnicity in Xinjiang have a higher KSHV seroprevalence than those of other Han populations in
mainland China.  However,  it  is  still  unclear  why there  is  such geographical  and  population
variation in KSHV distribution in China. In this work, we focused on the populations in the Kashgar
region and Urumqi  area,  where a  total  of  1294 research subjects  were randomly selected to
investigate the potential correlation between KSHV prevalence and different ethnicities in endemic
areas  of  Xinjiang,  and to  determine  risk  factors  that  may affect  KSHV infection  rates  or  KS
incidence. We identified a high seroprevalence of KSHV and high peripheral blood DNA infection in
the general Uygur and Han populations in both Urumqi and Kashgar regions of Xinjiang, and
determined that advancing age, low education level, and stationary population status affect KSHV
infection rates. Further, KSHV-positive Uygur participants were shown to have higher prevalence of
neutralizing antibodies and neutralizing antibody titers than KSHV-positive Han participants.
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INTRODUCTION
Kaposi’s sarcoma (KS) is a soft-tissue tumor most commonly
found in individuals with AIDS or immunodeficiency
(Boshoff et al., 2001). It can be classified into four forms
based on its clinical and epidemiological patterns: clas-
sical, AIDS-related, endemic, and iatrogenic KS (Cook-
Mozaffari et al., 1998). Kaposi’s sarcoma-associated
herpesvirus (KSHV), also known as human herpesvirus 8
(HHV8), was discovered in 1994 and is now known to
be the etiologic agent for KS, primary effusion lymphoma,
and multicenter Castleman’s disease (Cesarman et al.,
1995; Chang et al., 1994; Soulier et al., 1995; Whitby et al.,
1995).
The prevalence of KSHV infection parallels the incid-
ence of KS. KSHV seroprevalence is generally low to
moderate in western countries where KS incidence is
low, ranging from 3% to 23% (Ablashi et al., 2002). That
being said, KSHV seroprevalence is much higher in the
HIV-positive population (Bower et al., 2006). In Africa,
where there is a high incidence of endemic KS and an
HIV epidemic in the region, KSHV seroprevalence is
found to be as high as 50% in a number of African coun-
tries (Dedicoat et al., 2003; Minhas et al., 2008). In con-
trast, data from Asian countries suggest that KSHV sero-
prevalence is generally low (Ablashi et al., 2002; Fujii et al.,
1999). This is consistent with the much lower incidence
of KS in the region. In China, KS incidence in low
throughout most of the country, although a high incid-
ence of classical KS has been reported in the Xinjiang re-
gion (Fu et al., 2009; Wang et al., 2011). Xinjiang is a
region of autonomous rule in northwestern China that
borders Russia, Kazakhstan, Kyrgyzstan, Tajikistan,
Pakistan, Mongolia, Afghanistan, and India. The popula-
tion in this region is made up of a number of ethnic
groups, including Uygur, Han, Kazakh, and Hui. In par-
allel with the higher incidence of HIV infection, classic
KS and AIDS-associated KS are found mostly in those
of Uygur and Kazakh ethnicity (Dilnur et al., 2001).
KSHV prevalence also varies considerably among geo-
graphical regions and populations in the country, and it is
associated with the KS incidence. In most provinces of
China, KSHV seroprevalence is found to be less than 8%
in the general population. However, it is reported to be 19.3%
to 46.6% in the general adult population of Xinjiang
province, especially among the Uygur and Kazakh popu-
lations (Fu et al., 2009; Wang et al., 2011). Also notice-
able is that Xinjiang has one of the highest levels of HIV
infection in China; prevalence of KSHV among HIV-
positive individuals was 48.9% in Xinjiang from 2014
through 2015 (Liu et al., 2017). However, despite the high
KSHV prevalence and the high incidence of KS in Xinji-
ang, it remains unclear why there is such geographical
and population variation in KSHV distribution in China.
The Han population in Xinjiang shows a wider distri-
bution, predominantly residing in northern Xinjiang
where it accounts for about 70% of the total population
in comparison with the Uygur 25%. As the capital city of
Xinjiang, Urumqi accommodates a large proportion of
the Han population, which amounts to 72% of the total
local population and more than 10% of the total Han
population in Xinjiang. In addition, a relatively large por-
tion of the Han population in the Urumqi area is transi-
ent. Compared with the Han population, the distribution of
the Uygur population is relatively concentrated. The Uygur
population is mainly distributed in the southern region of
Xinjiang, accounting for more than 85% of the total Uygur
population in Xinjiang. From a regional point of view,
nearly 36% of the total Uygur population in Xinjiang Uygur
Autonomous Region live in Kashgar, accounting for
89% of the Kashgar region’s total population.
In this work, we focused on the populations in the
Kashgar region and the Urumqi area. The primary ob-
jective was to investigate the potential correlation between
KSHV prevalence and different ethnicities in endemic
areas of Xinjiang, and to determine whether environ-
mental factors or population migration affect KSHV in-
fection rates or KS incidence.
MATERIALS AND METHODS
Study participants and sample collection
A total of 1294 research subjects were randomly selected
from two regions of Xinjiang between January and
December 2015 using a stratified, multistage sampling.
Blood samples obtained from the research subjects were
divided into two groups. Group 1 included 700 plasma
samples and whole blood samples from individuals in
Urumqi. Group 2 comprised plasma samples from 594
individuals in Kashgar. Written informed consent was
obtained from all participants of the study. Additionally,
KSHV-seronegative plasma samples from anonymous
healthy blood donors from a local blood bank in Lincoln,
NE, USA, were used for assay controls.
Blood samples were collected in EDTA tubes, and
plasma was separated. Specimens were coded by a unique
identification number. All specimens were stored at –70 °C
until testing.
KSHV serological test
Two KSHV serological tests were used. First, all plasma sam-
ples were diluted 1:40 in PBS and tested using monoclonal-
enhanced immunofluorescence assays (mIFAs), as descri-
bed by Minhas et al. (2008). Briefly, BC3 cells were
stimulated with tetradecanoyl phorbol acetate, then fixed
with 4% paraformaldehyde and incubated with patient
plasma. Mouse monoclonal antihuman IgG (CRL-1786;
American Type Culture Collection, Manassas, VA, USA)
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was used as a secondary antibody and DyLight488-
conjugated donkey anti-mouse IgG (Jackson Immuno
Research, West Grove, PA, USA) was used as the tertiary
antibody. Second, Spodoptera frugiperda clone 9, expres-
sing three viral recombinant proteins, ORF73, ORF65,
and K8.1, was used (Fu et al., 2009). The procedure was
similar to the BC-3 immunofluorescence assay. A sample
was considered to be HHV-8-seropositive only if it was
positive at a standard serum dilution of 1:40 with both
the BC-3 and the S. frugiperda clone 9 assay. Each slide
was read independently by two experienced laboratory
workers. To determine the geometric mean titer (GMT)
of KSHV antibody, all positive plasma was diluted further
and tested by mIFA to estimate the KSHV antibody titer
of each sample.
DNA extraction and nested PCR for KSHV
detection
DNA was extracted from the whole blood samples using
a Gentra Puregene Blood kit (Qiagen, Germany) accord-
ing to manufacturer’s protocol. Extracted DNA was
subjected to polymerase chain reaction (PCR); the se-
quences of primers are listed in Supplementary Table 1.
PCR-positive samples were analyzed by nested PCR for
the presence of KSHV DNA. Each PCR reaction was
performed in a total volume of 25 μL, using 0.4 μmol/L
primers and a TaKaRa Ex Taq DNA polymerase kit
(TaKaRa Biotechnology) according to the manufacturer’s
protocol, with the exception that 2.5 units enzyme was
used. For control β-actin reactions, 1 μL genomic DNA
was used. For first- and second-round KSHV ORF26
PCR, 2 μL genomic DNA and 2 μL PCR product were
used, respectively. All reactions were performed under
the following conditions: 95 °C for 5 min, 35 cycles of
95 °C for 30 sec, 58 °C for 30 sec, 72 °C for 30 sec, and
one cycle of 72 °C for 7 min. Samples positive for the
ORF26 gene were then tested for presence of the KSHV
gB gene by nested PCR amplification. Positive results
for DNA detection were defined as those samples posi-
tive for both ORF26 and gB genes.
KSHV neutralization assay
Neutralizing antibodies against KSHV were detected for
all seropositive samples by a flow cytometry based
neutralization assay as described previously with minor
modifications (Kimball et al., 2004). Plasma was diluted
and mixed with recombinant KSHV expressing green
fluorescent protein (GFP; rKSHV.219) and incubated for
1 h at 37 °C. The virus and plasma mixture was added
into a 96-well plate seeded with 293 cells. After incuba-
tion for 72 h, green cells were counted by flow cytometry.
Results were confirmed by counting at least 100 cells
under a fluorescence microscope. A positive neutralizing
antibody outcome was defined as ≥ 50% reduction in
infectivity as compared with the seronegative control
serum. Positive plasma samples were diluted further to
determine the neutralizing antibody titer.
Statistical analysis
Original questionnaire data and laboratory results were
entered and managed with EpiData 3.0 (Odense, Denmark),
and then transferred to SPSS 17.0 (SPSS Inc., Chicago,
IL, USA) for further analysis. Differences in KSHV sero-
prevalence were measured by chi-square test or Fisher’s
exact test. The Mann-Whitney U-test was used to assess
the difference in GMTs of KSHV between Uygur and
Han ethnic groups. Correlation analysis was evaluated by
Pearson’s correlation coefficient. Power and sample size
estimation was done using Sample Power 2 (SPSS).
GraphPad Prism 5.0 (GraphPad, La Jolla, CA) was used
to construct figures. A P value of less than 0.05 was
considered statistically significant.
RESULTS
Characteristics of study participants
The characteristics of the two groups in the study population
(N = 1294) are summarized in Table 1. Group 1 partici-
pants (N = 700) aged 16–82 years were recruited from
Urumqi. Among them, 373 participants (53.3%) were of
Han ethnicity and 327 participants (46.7%) were of Uygur
ethnicity. Group 2 participants (N = 594) aged 15–86
years were recruited from Kashgar. comprising 282 part-
icipants (47.5%) of Han ethnicity and 312 participants
(52.5%) of Uygur ethnicity.
Table 1.  Characteristics of the study population
Characteristic
Group 1
(Urumqi)
Group 2
(Kashgar)
n (%) n (%)
Total Number 700 594
Ethnicity
Han 373 (53.3) 282 (47.5)
Uygur 327 (46.7) 312 (52.5)
Gender
Male 364 (52.0) 244 (41.1)
Female 336 (48.0) 350 (58.9)
Median Age (years) 43 48
Education
Elementary or below 273 (39.0) 330 (55.6)
Junior high or beyond 427 (61.0) 264 (44.4)
Population
stationary population 437 (62.4) 507 (85.4)
immigrated population 263 (37.6) 87 (14.6)
Prevalence of KSHV in Uygur and Han populations
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KSHV seroprevalence and antibody titers in
Urumqi and Kashgar regions
The overall KSHV seroprevalence of Uygur participants
was 40.4%, which was significantly higher than that of
Han ethnicity participants (31.1%) in Urumqi (P < 0.05)
(Figure 1A). The end-point titer of all KSHV-positive
Han and Uygur plasma samples was determined, and we
observed that the GMT of Uygur ethnicity individuals
was significantly higher than that of the Han ethnicity
individuals (P < 0.001) (Figure 1B). The KSHV seropre-
valence of Uygur participants in Kashgar was 59.9%,
which was also significantly higher than that of Han
participants (21.3%) (P < 0.001) (Figure 1C), and the
GMT of all KSHV-positive Uygur ethnicity individuals
was significantly higher than that of all KSHV-positive
Han ethnicity individuals (P < 0.001) (Figure 1D).
Risk factors associated with KSHV
seroprevalence
The association between KSHV seroprevalence and the
characteristics of the 1294 participants stratified by geo-
graphic region is presented in Table 2. In the Urumqi
group of 700 study participants, 116 Han (31.1%) and
132 (40.4%) Uygur were KSHV seropositive. KSHV
infection was correlated with advancing age (P = 0.005)
and education level (P = 0.047). Interestingly, partici-
pants in the stationary population exhibited high serum
prevalence of KSHV (38.4%). In the Kashgar group of
594 study participants, 60 Han (21.3%) and 187 (59.9%)
Uygur were KSHV seropositive. Again, KSHV infection
was correlated with advancing age (P = 0.047) and
education level (P = 0.003). The stationary population
showed higher KSHV seroprevalence (44.4%) than the
immigrated population (25.3%). No clear correlation was
observed between KSHV infection and gender in either
Urumqi or Kashgar participants.
Peripheral blood DNA positive rate and risk
factors in Urumqi region
All peripheral blood DNA samples from Urumqi were
analyzed using nested PCR for the presence of KSHV
DNA based on primers for the ORF26 and gB genes.
Reaction products of ORF26 and gB by nested PCR in
the second round showed that the target gene fragments
were amplified in a position-specific manner, and the
product size was 174 bp and 383 bp, respectively (Supple-
menaty Figure S1A, 1B). Samples scored positive for
KSHV DNA detection were positive for amplification of
both the ORF26 and gB genes. Table 3 presents the
KSHV DNA positive rate associations with ethnicity,
gender, age, and education, and stratified by population
status (stationary or immigrated). There were 26.9%
(88/327) of Uygur participants and 17.4% (65/373) of
Han participants whose peripheral blood DNA showed
KSHV-positive results, which indicated a significant
difference (P = 0.002). Among all participants, the KSHV
DNA positive rate increased significantly with age from
18.9% in those aged < 50 years to 25.7% in those aged ≥
50 years (P = 0.03). Furthermore, there was a significant
difference in the KSHV DNA positive rate with respect
to population status (P = 0.018), from 17.1% in the im-
migrated population to 24.7% in the stationary popula-
tion. A correlation of borderline significance was detected
between KSHV DNA positive rate and education level
(P = 0.052), while no associations were observed between
KSHV infection and gender.
KSHV neutralizing antibody prevalence and
titers
Given the high prevalence of KSHV infection in people
of both Uygur and Han ethnicity in Xinjiang, and the
high KSHV antibody titer in those of Uygur ethnicity,
we investigated the prevalence of neutralizing antibodies
in all KSHV-positive participants in Urumqi. We found
that 17/132 (12.9%) seropositive Uygur participants had
detectable levels of neutralizing antibodies. In contrast,
only 5/116 (4.3%) KSHV-seropositive Han participants
had detectable neutralizing antibody (Figure 2A). Since
there was a significant difference (P = 0.018) in the
 
Figure 1. KSHV seroprevalence and antibody titers in
Han and Uygur groups in the study population of Urumqi
and Kashgar, Xinjiang. (A, C) Prevalence of KSHV in-
fection in Han and Uygur populations of Urumqi and
Kashgar. (B, D) Comparison of KSHV antibody titers in
Han and Uygur populations of Urumqi and Kashgar.
Jun Zheng et al.
 
www.virosin.org OCTOBER 2017   VOLUME 32  ISSUE 5  399
prevalence of neutralizing antibodies between samples
from individuals of Uygur and Han ethnicity, all neu-
tralizing antibody positive samples were further titrated
to investigate whether there were differences in the neu-
tralizing antibody titers within these groups. Figure 2B
compares the GMT of neutralizing antibodies of all sam-
ples that had detectable neutralizing antibodies between
Han and Uygur participants. The result clearly demon-
strated that the GMT of neutralizing antibodies in those
of Uygur ethnicity was significantly higher than that in
those of Han ethnicity (P = 0.026).
DISCUSSION
This is the first study to our knowledge conducted to
compare KSHV seroprevalence and antibody titers be-
tween people of Uygur and Han ethnicity in the Urumqi
and Kashgar regions of Xinjiang, China. Moreover, it is
also the first comparison between the prevalence and
titers of neutralizing antibodies in plasma samples from
Uygur and Han individuals from an endemic area. Xinjiang
has a unique mix of various ethnicities and has been re-
ported to be an endemic area for KS and KSHV infection.
He et al. (2007) reported that more than 95% of KS cases
were observed in minority groups, particularly of Uygur
ethnicity. Xinjiang’s vast territory, in the center of the
Eurasian continent, is inhabited by minorities with
distinctive languages, cultures, religions, and lifestyles,
unique diets, and different genetic backgrounds. In
Table 2.  The associations of KSHV seroprevalence with population characteristics stratified by geographic region from
Xinjiang, China
Characteristic Cases (n)
Urumqi χ2 P Cases (n)
Kashgar χ2 PKSHV + (%) KSHV - (%) KSHV + (%) KSHV - (%)
Ethnicity
Han 373 116 (31.1) 257 (68.9) 6.542 0.011 282 60 (21.3) 222 (78.7) 91.132 0.000
Uygur 327 132 (40.4) 195 (59.6) 312 187 (59.9) 125 (40.1)
Gender
Male 364 136 (37.4) 228 (62.6) 1.240 0.265 244 105 (43.0) 139 (57.0) 0.359 0.549
Female 336 112 (33.3) 224 (66.7) 350 142 (40.6) 208 (59.4)
Age
< 50 397 123 (31.0) 274 (69.0) 7.926 0.005 286 107 (37.4) 179 (62.6) 3.948 0.047
≥ 50 303 125 (41.3) 178 (58.7) 308 140 (45.5) 168 (54.5)
Education
Elementary
or below 273 109 (39.9) 164 (60.1) 3.958 0.047 330 155 (47.0) 175 (53.0) 8.871 0.003
Junior high
or beyond 427 139 (32.6) 288 (67.4) 264 92 (34.8) 172 (65.2)
Population
Stationary
population 437 168 (38.4) 269 (61.6) 4.623 0.032 507 225 (44.4) 282 (55.6) 11.142 0.001
Immigrated
population 263 80 (30.4) 183 (69.6) 87 22 (25.3) 65 (74.7)
 
Figure 2. Prevalence and titer of KSHV neutralizing an-
tibodies in Han and Uygur groups in the study popula-
tion in Urumqi, Xinjiang. (A) Percentage prevalence of
neutralizing antibodies in individuals of Han and Uygur
ethnicity.  (B)  KSHV neutralizing antibody titers (log2
transformed)  in  samples  from Han and Uygur  parti-
cipants. GMT of neutralizing antibodies in each group is
also marked.
Prevalence of KSHV in Uygur and Han populations
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addition, the minority populations in the region are
relatively less mobile comparing with Han ethnicity.
Several studies have investigated KSHV seroprevalence
in people of Uygur or Han ethnicity in Xinjiang, but none
have dealt with seroprevalence of KSHV, peripheral blood
KSHV DNA positive rate, and the prevalence of neutra-
lizing antibodies, and identified risk factors associated
with KSHV prevalence among populations of Uygur and
Han ethnicity from different regions.
In this study, the overall KSHV seroprevalence and
the endpoint titer of Uygur participants were significantly
higher than those of Han participants in both Urumqi
and Kashgar regions. Previous studies have shown a high
KSHV seroprevalence in Xinjiang, in the range of 12.5%
to 48.0%, depending on differences in study populations
(Fu et al., 2009; Du et al., 2000; Wang et al., 2010; He et al.,
2007). The seroprevalence of KSHV among the general
Uygur population from South and North Xinjiang was
23.1% and 25.9%, respectively (Wang et al., 2011).
Compared with the Han population in mainland China,
which has a very low serum-positive rate, the significantly
increased rate in the Han population in Xinjiang also presents
a thought-provoking question. This study mainly concen-
trated on the Chinese Han population that immigrated to
Xinjiang during the 1950s to 1970s. Due to historical
background and traditional moral values, those of Han
nationality conform very strictly to single-partner sexual
relationships. Moreover, because of religious differences
between Uygur and Han populations, interracial mar-
riage, sexual relations, and drug needle sharing between
these groups are extremely rare. Therefore, the possibil-
ity of sexual contact is unlikely. Is it possible that the
Han population itself belongs to a high-risk group for
high KSHV positive rate among the Han population in
Xinjiang? This possibility is unlikely, considering the
very low positive rate among the Han population in
mainland China. At the time the Han population immig-
rated to Xinjiang, both health care and living conditions
were primitive and difficult in Xinjiang, and there was a
high likelihood of horizontal transmission.
In comparison with KSHV seroprevalence, the posit-
ive rate of peripheral blood DNA was relatively low.
KSHV belongs to the gamma herpesvirus family and is
similar to other herpesviruses. After infection, it can pro-
duce two different life cycles, latent infection and lytic
replication, and can reside in the host for a lifetime. After
the initial infection, the viral genome continues to exist
in the nucleus in the form of covalent rings. The virus is
first evading host immune clearance. Furthermore, when
the body is exposed to various adverse stresses, the de-
creased immune status allows activation of the latent
virus and it enters the state of lytic replication. This then
produces a large number of virus particles, which further
infect B lymphocytes and play an extremely important
role in induction of carcinogenesis. Therefore, the detec-
tion rate of KSHV DNA in peripheral blood mononuc-
lear cells (PBMC) is relatively low. Considering the de-
tection rate of the PBMC genome (about 1.33%–22.5%),
both domestically and internationally, this provides fur-
ther evidence that Xinjiang is a high-prevalence area for
KSHV. As previously reported, KSHV DNA positive
rates were 4.5% and 22.5% among donors in Tanzania
(Enbom et al., 2002) and Central Africa (Belec et al.,
1998). According to another report, the detection rate of
KSHV DNA in 59 blood donors in Italy was 9% (Bigoni
et al., 1996). The positive KSHV DNA rate among 230
healthy blood donors in northeast China was 7.8%
(Wang et al., 2002). It is worthwhile noting that there is
no direct correlation between the positive rate of serum
and the positive rate of DNA in peripheral blood. In other
words, the positive rate of serum or DNA reflects the
KSHV infection in different groups. The positive rate of
serum is mainly detected by serum antibody, while the
DNA test can be regarded as antigen expression. In one
study, it was reported that the detection rate of KSHV DNA
in PBMC was 16.5% in 158 healthy KSHV-seropositive
adults (Brown et al., 2005). In another work, the KSHV
DNA in PBMC was detected only in one person out of
12 KSHV-seropositive healthy individuals (Vitale et al.,
2000).
Table 3.  The associations of KSHV DNA positive rate with
population characteristics in Urumqi region of Xinjiang.
Characteristic Cases(n)
KSHV
+ (%)
KSHV
- (%) χ
2 P
Ethnicity
Han 373 65 (17.4) 308 (82.6) 9.178 0.002
Uygur 327 88 (26.9) 239 (73.1)
Gender
Male 364 72 (19.8) 292 (80.2) 1.915 0.166
Female 336 81 (24.1) 255 (75.9)
Age
< 50 397 75 (18.9) 322 (81.1) 4.722 0.030
≥ 50 303 78 (25.7) 225 (74.3)
Education
Elementary
or below 354 88 (24.9) 266 (75.1) 3.778 0.052
Junior high
or beyond 346 65 (18.8) 281 (81.2)
Population
Stationary
population 437 108 (24.7) 329 (75.3) 5.558 0.018
Immigrated
population 263 45 (17.1) 218 (82.9)
Jun Zheng et al.
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Further analysis of the risk factors associated with
KSHV indicated that KSHV infection was associated
with advancing age, low education level, and stationary
population status. These results are consistent with those
of several other studies, which described an increase in
seroprevalence of KSHV with age in different popula-
tions (Baillargeon et al., 2001; Zavitsanou et al., 2007;
2010). This correlation may be related to the natural
aging process, and hypoimmunity may be a promoting
agent for KSHV infection. In this study, the educational
level of the population was relatively low, especially in
the Kashgar area, where nearly half of the people had an
education level below junior high school. Understand-
ably, general knowledge and awareness about health is-
sues is far more limited in the population in this region.
Therefore, attaining a higher education level is a protec-
tion factor for KSHV infection. Furthermore, the mobil-
ity of the population in Xinjiang region is relatively low.
The stationary population is mostly of Uygur ethnicity,
and these residents are relatively concentrated. To a large
extent, the traditional lifestyle and behavior of the Uygur
people has remained unchanged over the past two dec-
ades. In addition, the lifestyle and eating habits of some
Han populations who have lived in Xinjiang for a long
time may have become adversely affected, with quality
of life and education level reflecting their low socioeco-
nomic status. Such conditions might have facilitated the
transmission of KSHV infection.
The neutralizing antibody response is known to play
an important role in preventing viral infection (Yoshida
et al., 2002) and may be protective against the develop-
ment of KS (Kimball et al., 2004). Our finding that Uygur
participants had a high prevalence and increased titers of
neutralizing antibodies should not be interpreted to mean
that neutralizing antibodies are not protective in the case
of KSHV infection. It is quite possible that neutralizing
antibodies have very different roles during primary KSHV
infection and later on during persistent long-term infec-
tion. In chronically infected KS patients, neutralizing an-
tibodies may have a role limited only to controlling the
spread of KSHV. However, during primary infection,
neutralizing antibodies can prevent KSHV infection if
they are present at the time of exposure, as would be the
case if elicited by a vaccine prior to primary infection. A
prophylactic vaccine that can strongly induce neutraliz-
ing antibodies could be useful to prevent infection in
KSHV endemic populations. In addition, longitudinal
studies are needed to investigate the association between
the presence of neutralizing antibodies and the develop-
ment of KS in this population.
In summary, we identified a high seroprevalence of
KSHV and high peripheral blood DNA infection among
the general Uygur and Han populations in both Urumqi
and Kashgar regions in Xinjiang. Through analysis of the
potential correlation between KSHV prevalence and risk
factors in endemic areas of Xinjiang, it can be determ-
ined that advanced age, low education level, and station-
ary population status likely affect KSHV infection rates.
KSHV-positive Uygur participants showed higher pre-
valence of neutralizing antibodies and neutralizing anti-
body titers than KSHV-positive Han participants. Fur-
ther studies on KSHV prevalence and more extensive
risk factor analysis, such as living arrangements, hygiene
conditions, and food-sharing practices, are needed to ex-
plore the epidemiology of KSHV infection in this popu-
lation.
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